Eswatini

Resource
July 16, 2019
Our 9th Research Digest assembles 87 abstracts published from May through June 2019 that feature evidence from Botswana (6), Eswatini/Swaziland (2), Malawi (12), Mozambique (4), South Africa (46), Tanzania (4), Zambia (7) and Zimbabwe (17).
Event
July 16, 2019

Have you been looking for an easier and more accurate way to quantify pediatric HIV treatment needs over time?

News
June 26, 2019
Results of a pivotal clinical trial among 7,829 women ages 16-35 in East and Southern Africa provide important evidence to help inform women’s choices for contraception and HIV prevention. The Evidence for Contraceptive Options and HIV Outcomes (ECHO) Study found no substantial difference in HIV risk among women using the three methods of contraception in the study – the copper-releasing intrauterine device (Cu-IUD), a levonorgestrel (LNG) implant (Jadelle) and depot medroxyprogesterone acetate-intramuscular (DMPA-IM), also known as Depo-Provera.
Resource
June 25, 2019
Injectable, intrauterine, and implantable contraceptives have been prioritised for programmatic delivery because of high contraceptive efficacy and safety. Robust evidence on the relative risks, particularly HIV susceptibility, and benefits of these contraceptive methods is important to inform women's decision making, provider counselling, and policy maker and regulatory decisions. Our primary objective was to compare HIV incidence among women using DMPA-IM, a copper IUD, or a levonorgestrel (LNG) implant.
Resource
May 27, 2019

The USAID/TSP HIV Child and Adolescent ARV Procurement Forecasting Tool is intended to assist program managers, clinicians and support staff in quantifying and budgeting for a program’s child and adolescent ARV

Resource
May 12, 2019
In our 8th issue of our Research Digest, we have assembled 64 abstracts published from March through April 2019 that feature evidence from Botswana (2), Eswatini (2), Lesotho (2), Malawi (12), Mozambique (4), Namibia (1), South Africa (32), Tanzania (3), Zambia (11) and Zimbabwe (14).
Resource
April 12, 2019
Drawing on Goffman's stigma work, we aimed to investigate how stigma may influence the engagement of clinically asymptomatic people living with HIV (PLHIV) with Treat-all HIV care in Shiselweni, Eswatini (formerly Swaziland). This longitudinal research comprised 106 interviews conducted from August 2016 to September 2017, including repeated interviews with 30 PLHIV, and one-off interviews with 20 healthcare workers.
Resource
April 12, 2019
Treat-all is being implemented in several African settings, in accordance with 2015 World Health Organisation guidelines. The factors known to undermine adherence to antiretroviral therapy (ART) may change in the context of Treat-all, where people living with HIV (PLHIV) increasingly initiate ART at earlier, asymptomatic stages of disease, soon after diagnosis. This paper aimed to examine the asymptomatic PLHIV's experiences engaging with early ART initiation under the Treat-all policy, including how they navigate treatment-taking over the longer term.
Resource
April 2, 2019
In this, our 7th, issue, we have assembled 67 abstracts published from January through February 2019 that feature evidence from Botswana (3), Eswatini (2), Lesotho (2), Malawi (16), Mozambique (3), South Africa (40), Tanzania (2), Zambia (3) and Zimbabwe (7).
Resource
March 19, 2019

The U.S. President's Emergency Plan for AIDS Relief (PEPFAR) delivers life-saving services to people affected by the HIV/AIDS epidemic in 36 country and regional programs. Founded in 2003, PEPFAR is the largest investment in combating a single disease by a single country in history.